Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Coffee and Arterial Stiffness Evaluation (CASE)

12 de noviembre de 2026 actualizado por: Charlotte E Mills, University of Reading

Coffee and Arterial Stiffness: Effects on Chronic Coffee Intake on Markers of Vascular Function, Cardiometabolic and Liver Health

This study aims to investigate whether twelve weeks of daily coffee consumption can improve blood vessel elasticity (arterial stiffness) in adults typical of the UK population who are currently non-habitual coffee consumers. Additionally, the effects on cardiometabolic disease risk markers, liver health markers, cognitive function and inter-individual genetic variations in response to coffee consumption will be examined.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Coffee has gained interest for its role in the prevention of non-communicable diseases such as heart and liver disease. Observational studies have reported that regular coffee consumption (2-4 cups per day) is associated with reduced risk of cardiovascular disease, type 2 diabetes, and overall mortality. However, these observational studies do not prove direct causality, requiring the need for well-designed randomized controlled trials. Additionally, most evidence comes from habitual coffee drinkers, and there is limited understanding of whether introducing coffee to non-habitual consumers can provide similar health benefits, particularly in individuals that are typically reflective of the UK population.

This trial aims to provide direct causal evidence to the potential health effects of coffee consumption on risk markers for the development of cardiometabolic disease (such as type 2 diabetes, heart and liver diseases). To ensure the potential impact of habitual coffee consumption is minimised as a confounding factor, non-habitual coffee consumers (coffee-naïve) will be recruited. To maximise recruitment and adherence in the study, the coffee intervention is being provided in a tablet formulation (as opposed to a liquid drink formulation typical taken). In a previous pilot study conducted in 2025, the biological activity of the coffee tablet formulation is expected to be deemed bioequivalent compared to the liquid drink.

A 2-armed, double-blind, randomized controlled parallel trial will be conducted in participants that reflect the general population (estimated using UK representative data from the National Diet and Nutrition Survey). The primary outcome is the effect of coffee consumption on arterial stiffness (measured by cardio-ankle vascular index (CAVI)), an important prognostic marker of vascular aging and cardiovascular disease. Secondary outcomes will assess the impact of coffee consumption on cardiometabolic disease risk markers, liver health markers, cognitive function and genetic factors driving inter-individual response. This will be compared to a coffee-free control.

Study participation will require two visits to the Hugh Sinclair Unit of Human Nutrition (HSU), University of Reading, UK. For the first visit, participants will arrive having fasted overnight, consumed a standardised evening meal, and having followed lifestyle restrictions in the preceding days. Baseline anthropometric measures, blood pressure, CAVI measures, cognitive functions scores will be performed in addition to collecting a fasting blood sample (up to 50ml in total). Additionally, participants will be asked to provide a 24-hour urine sample during the same visit. At the end of the first study visit, participants will be randomised, stratified by age, gender and body-mass index (BMI), and receive their intervention bottles containing tablets to take on a daily basis over the 12-week study period. The second study visit will repeat the same procedures outlined at the end of 12 weeks.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

65

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Berkshire
      • Reading, Berkshire, Reino Unido, RG6 6DZ
        • Hugh Sinclair Unit of Human Nutrition
        • Contacto:
        • Sub-Investigador:
          • Kim G Jackson, PhD
        • Sub-Investigador:
          • Anisha Wijeyesekera, PhD
        • Sub-Investigador:
          • TiJesu Akeredolu, MPharm
        • Sub-Investigador:
          • Lolwa Alawadhi, MSc
        • Sub-Investigador:
          • Altaf Farraj, MSc

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Males and females
  • Aged between 40 to 75 years
  • Low habitual coffee consumption (less than 3 cups per week) (over the past 4-week period)
  • Body mass index (BMI) between 18.5-32.0kg/m^2 (inclusive)
  • Total cholesterol ≤6.5 mmol/L
  • Fasting triglycerides <1.7 mmol/L
  • Fasting glucose ≤ 6.1 mmol/L
  • Blood pressure 90/60 - 140/90 mmHg (inclusive)

Exclusion Criteria:

  • Sensitivity to coffee or caffeine
  • Regular consumption of caffeinated products or drinks; including tea, energy drinks or caffeine tablets (over 350 mg caffeine per week) or unwilling to stop drinking coffee during the intervention period
  • Current smoking and vaping use
  • Medical history of chronic diseases (cancer, hypertension, type 2 diabetes, ischaemic attacks and/or any other cardiovascular related diseases, gastro-intestinal disorders, hyperlipidaemia, kidney or liver disease)
  • Haemoglobin <115 g/L for females or <130 g/L for males
  • Prescribed any medication relating to the study outcome measures (such as blood pressure lowering, anti-inflammatories or blood thinners)
  • Current use or past use of antibiotics within 6 months
  • Drinking more than the recommended intake for alcohol (>14 units of alcohol per week)
  • Current undertaking or planning to start a weight reducing regimen
  • Taking any supplements (vitamins, minerals, prebiotics and probiotics)
  • Any other medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (e.g. pacemaker)
  • Parallel participation in another intervention study
  • Pregnancy, planning a pregnancy in the next 6 months or breastfeeding
  • NHS blood donation (470 ml) in the last 3 months

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Coffee

This group will consume 5.4g of a commercially available instant coffee, provided in a tablet formulation (9 tablets daily).

Commercially available instant coffee (5.4g), will be provided as 9 tablets (equivalent to 3 tablets per cup, therefore total 3 cups daily). This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.

Comparador de placebos: Control

This group will consume a coffee-free control, provided in a tablet formulation (9 tablets daily).

Coffee-free control (microcrystallinecellulose (non-active)) will be provided as 9 tablets. This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cardio-ankle vascular index
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Cardio-ankle vascular index (CAVI) score will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) and attachment of a PCG microphone (measuring heart sounds during the cardiac cycle) on the sternum using a VaSera VS-2000 device on study visits. No fixed scale range is present, lower scores indicate an improvement in outcome.

Week 0 (baseline), Week 12 (final visit)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fasting coffee bioactives concentrations and polyphenol metabolite concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Plasma concentrations of key coffee bioactives (e.g. caffeine, chlorogenic acids, trigonelline) and polyphenol metabolites will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry, concentration unit of measure (microgram per millilitre).

Week 0 (baseline), Week 12 (final visit)
Fasting lipid profile concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum total cholesterol (TC), triacylglycerol, high-density lipoprotein cholesterol (HDL-C), non-esterified fatty acids and apolipoprotein B will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). Low-density cholesterol concentrations will be calculated from TC concentrations and HDL-C concentrations using the Friedewald formula.

Week 0 (baseline), Week 12 (final visit)
Fasting insulin concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum insulin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (IU per millilitre).

Week 0 (baseline), Week 12 (final visit)
Fasting glucose concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum glucose will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (millimolar per millilitre).

Week 0 (baseline), Week 12 (final visit)
Fasting Haemoglobin A1C concentrations of glycaemic control measures
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Haemoglobin (Hb) A1C will be measured from a fasting whole blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (%).

Week 0 (baseline), Week 12 (final visit)
Fasting estimate of insulin resistance
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the fasting glucose and insulin data. Scale range: <1 - 5+, lower scores indicate an improvement in outcome.

Week 0 (baseline), Week 12 (final visit)
Fasting estimate of insulin sensitivity
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the fasting glucose and insulin data. Scale range: <0.25 - 0.45+, higher scores indicate an improvement in outcome.

Week 0 (baseline), Week 12 (final visit)
Fasting liver enzyme and function concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transferase (AST), gamma-glutamyl transferase (GGT) and total bilirubin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (unit per liter).

Week 0 (baseline), Week 12 (final visit)
Fasting concentrations of kidney function measures
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum uric acid and creatinine will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre).

Week 0 (baseline), Week 12 (final visit)
Fasting concentrations of inflammatory markers
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum interleukin (IL) 1b, IL-6, high sensitivity C-reactive protein, tumour necrosis factor alpha, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (picogram per millilitre)

Week 0 (baseline), Week 12 (final visit)
Fasting brain-derived neurotrophic factor concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum brain-derived neurotrophic factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

Week 0 (baseline), Week 12 (final visit)
Fasting vascular endothelial growth factor concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Serum vascular endothelial growth factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

Week 0 (baseline), Week 12 (final visit)
Fasting oxidised low density lipoprotein cholesterol concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Plasma concentrations of oxidised low density cholesterol will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

Week 0 (baseline), Week 12 (final visit)
Fasting trimethylamine N-oxide concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Plasma concentrations of trimethylamine N-oxide will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry.

Week 0 (baseline), Week 12 (final visit)
Fasting gut hormone concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Plasma concentrations of C-peptide, gastric inhibitory polypeptide, glucagon-like receptor-1 and ghrelin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via Luminex

Week 0 (baseline), Week 12 (final visit)
Fasting estimated nitric oxide concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Plasma estimated concentrations of nitric oxide (nitrate and nitrite) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via chemiluminescence/LCMS.

Week 0 (baseline), Week 12 (final visit)
Urinary metabolomics
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Untargeted metabolomics will be performed on pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy

Week 0 (baseline), Week 12 (final visit)
Urinary creatinine concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Urinary concentrations of creatinine will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via clinical chemistry analyser

Week 0 (baseline), Week 12 (final visit)
Urinary F2-isoprostanes concentrations
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Urinary concentrations of F2-isoprostanes will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry.

Week 0 (baseline), Week 12 (final visit)
Identification of gut microbiota composition
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Gut microbiome composition will be identified and assessed using RNA sequencing from a stool sample, provided on day prior to study visits.

Week 0 (baseline), Week 12 (final visit)
Cognitive function
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Assessment of cognitive function will be performed using Millisecond Inquisit 7 software on study visits. No fixed scale range is present, higher scores indicate an improvement in outcome.

Week 0 (baseline), Week 12 (final visit)
Clinic blood pressure
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Blood pressure will be measured using a blood pressure monitor on study visits.

Week 0 (baseline), Week 12 (final visit)
Ankle Brachial Index
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Ankle Brachial Index will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) using a VaSera VS-2000 device on study visits. Scale range: <0.5 - 1.4+, higher scores indicate an improvement in outcome.

Week 0 (baseline), Week 12 (final visit)
Lean body mass
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Body lean mass will be measured by bioelectrical impedance using the Tanita scale on study visits.

Week 0 (baseline), Week 12 (final visit)
Body fat percentage
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Body fat percentage will be measured by bioelectrical impedance using the Tanita scale on study visits.

Week 0 (baseline), Week 12 (final visit)
Body-mass index
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Height will be measured using a stadiometer on the first study visit. Weight will be measured using the Tanita scale on both study visits.

Week 0 (baseline), Week 12 (final visit)
Hip and waist circumference
Periodo de tiempo: Week 0 (baseline), Week 12 (final visit)

Hip and waist circumference will be measured using a non-stretch tape on study visits.

Week 0 (baseline), Week 12 (final visit)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Abbe Davy, BSc, University of Reading

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de noviembre de 2026

Finalización primaria (Estimado)

30 de julio de 2027

Finalización del estudio (Estimado)

30 de agosto de 2030

Fechas de registro del estudio

Enviado por primera vez

22 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • UREC 26/31

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All anonymised IPD that underlie results in a publication and analytical code for statistical analysis

Marco de tiempo para compartir IPD

Anonymised data will be made available on reasonable request to the study Chief Investigator one year after manuscripts have been published.

Criterios de acceso compartido de IPD

For data sharing and preservation, anonymised IPD will be archived in the University of Reading Research Data Archive. Access will be overseen by the project Chief Investigator (Associate Professor Charlotte Mills).

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .